Exogenous surfactant therapy in non-respiratory distress syndrome.
There is clinical evidence of the benefit of exogenous surfactant therapy to certain neonates with severe respiratory failure, diaphragmatic hernia, pneumonia and meconium aspiration syndrome. There still remain, however, important unanswered questions regarding, for example, optimum dosage and method of administration; appropriate randomized trials must be undertaken.
Greenough
A
A
Department of Child Health, King's College School of Medicine and Dentistry, London, UK.
D000818:Animals; D002417:Cattle; D004195:Disease Models, Animal; D006548:Hernia, Diaphragmatic / Q000188:drug therapy; D065630:Hernias, Diaphragmatic, Congenital; D006801:Humans; D007231:Infant, Newborn; D008471:Meconium Aspiration Syndrome / Q000188:drug therapy / Q000209:etiology; D011014:Pneumonia / Q000151:congenital / Q000188:drug therapy; D011663:Pulmonary Surfactants / Q000172:deficiency / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats; D012120:Respiration Disorders / Q000151:congenital / Q000188:drug therapy* / Q000503:physiopathology; D012756:Sheep
D011663:Pulmonary Surfactants